HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrutiny Of Direct Selling Businesses Prompts Avon To Leave Trade Group

This article was originally published in The Tan Sheet

Executive Summary

Avon says its own policies provide better protections to sales representatives than U.S. DSA’s code of ethics. DSA efforts to refute pyramid scheme allegations against some direct sellers help “a few specific brands” at the expense of the rest of the industry, the firm contends.

You may also be interested in...



China Regulatory Probe Slows Nu Skin Growth After Record Year

The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.

Avon Announces More Layoffs, Plans To Exit Ireland

As part of Avon Products Inc.’s previously announced $400 million Cost Saving Initiative, the firm has announced plans to exit Ireland and eliminate 400 positions globally, among other measures.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel